Atrial Cardiomyopathy in Patients With Stroke of Undetected Mechanism
NCT ID: NCT03830983
Last Updated: 2023-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
150 participants
OBSERVATIONAL
2019-03-08
2023-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Coronary CT Angiography Using 320-Row Volume CT in Patients With Atrial Fibrillation
NCT00968279
Myocardial Damage In Patients With Cerebral Infarction
NCT00306579
Diagnostic Approach of Early Atrial Fibrillation, Silent Stroke and Cognitive Disorder in Patients With High-risk
NCT05772806
Coronary Arteriosclerosis in Patients With Acute Ischemic Stroke
NCT00701818
Does Coronary Angiography Cause Cognitive Dysfunction?
NCT01428947
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The goal of this study is to evaluate left atrial structural and functional abnormalities in patients with stroke of likely cardio-embolic origin compared with healthy age and sex matches controls and patients with atherosclerotic stroke using cardiac MRI.
Background:
Despite standard work up for the etiology of ischemic stroke, about 30% of the cases remain unexplained. It is increasingly accepted that these unexplained cases arise from disease outside of the brain. Paroxysmal AF (Atrial fibrillation) may often be suspected as the source but fewer than one third of patients with stroke of undetermined source manifest AF in any form even after 3 years of continuous heart rhythm monitoring. Emerging evidence suggest that atrial functional and structural abnormalities may convey a comparable risk of stroke in which AF is only one of several features. These abnormalities have been termed "atrial cardiomyopathy" and may be an efficient and practical approach to identify patients at high risk of AF and ischemic stroke.
Methods and materials:
Cross sectional and prospective cohort study with 3 different groups: 50 patients with stroke of undetected mechanism, 50 patients with atherosclerotic stroke (large or small vessel disease) admitted to the University Hospital of Bispebjerg and Frederiksberg and 50 sex and age matched controls with no history of stroke or AF from the Copenhagen City Heart Study (Ă˜BUS) will be included during a 2 year-period. The study will measure atrial structural abnormalities using cardiac magnetic resonance imaging (MRI) and atrial functional abnormalities by cardiac MRI and echocardiography. A 1 year follow up will examine the incidence of silent brain infarction with MRI and incidence of stroke, atrial fibrillation, acute myocardial infarction and cardiovascular death. Secondary endpoints are to examine the association of functional and structural changes found by MRI with echocardiography, rhythm abnormalities and biomarkers with the purpose of finding clinical easily applicable methods to diagnose atrial cardiomyopathy.
Expected outcome and perspectives:
The investigators hypothesize that patients with stroke of likely cardio-embolic origin have significantly more atrial fibrotic degeneration and reduced atrial emptying function than patients with atherosclerotic stroke and the control subjects. The investigators expect a higher incidence of silent brain infarction in the group with stroke of likely cardio-embolic origin. With atrial cardiomyopathy investigated thoroughly in patients with stroke of likely cardio-embolic origin the future work-up and treatment strategies could be more efficient and may thus improve the prognosis in terms of mortality and disability for a considerable number of patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stroke of likely cardioembolic cause or undetected mechanism
Lesions in at least one territory on MRI \& absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels \>50% in arteries supplying the ischemic area(s) \& absence of severe small vessel disease including micro-bleeds on Patients with central retinal artery occlusion documented by perimeter and absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels \>50% \& absence of severe small vessel disease including micro-bleeds on MRI are included independent of acute MRI findings.
No interventions assigned to this group
Atherosclerotic stroke
Large vessel stroke: Acute lesions in one vascular territory on MRI, significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels \>50% leading to the infarcted territory \& absence of severe small vessel disease including micro-bleeds on MRI Small Vessel stroke: MRI documenting lacunar infarction, absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels \>50% and presence of severe small vessel disease possibly including micro bleeds.
No interventions assigned to this group
Controls
Age and sex matched healthy controls with no history of stroke or AF.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Lesions in at least one territory on MRI \& absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels \>50% in arteries supplying the ischemic area(s) \& absence of severe small vessel disease including micro-bleeds on MRI.
Patients with central retinal artery occlusion documented by perimeter and absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels \>50% \& absence of severe small vessel disease including micro-bleeds on MRI are included independent of acute MRI findings.
2. Large or small vessel stroke (atherosclerotic stroke):
Large vessel stroke: Acute lesions in one vascular territory on MRI, significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels \>50% leading to the infarcted territory \& absence of severe small vessel disease including micro-bleeds on MRI Small Vessel stroke: MRI documenting lacunar infarction, absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels \>50% and presence of severe small vessel disease possibly including micro bleeds.
3. Ischemic stroke within 30 days prior to inclusion
4. Age \> 18 years
5. Life expectancy of at least one year
6. Informed consent
* Stenosis: % defined by Ultrasound
* Small vessel disease: defined according to STRIVE criteria
1\. Age and sex matched healthy controls. Matched with the group with stroke of likely cardioembolic stroke.
Exclusion Criteria
2. Other major cardio-embolic risk sources assumed as cause of stroke (e.g. endocarditis, myocardial infarction within last 4 weeks, prosthetic cardiac valve)
3. Contraindications to MRI (Including eGFR\<30 or other contraindications for the contrast agent used during Cardiac MRI)
4. Assumed unable to participate in the study by investigator (including but not restricted to psychiatric condition, dementia)
1. History of stroke or AF
2. Contraindications to MRI (Including eGFR\<30 mL/min/1.73 m2 or other contraindications for the contrast agent used during Cardiac MRI)
3. Assumed unable to participate in the study by the investigator (For the same reasons listed above)
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Lundbeck Foundation
OTHER
University Hospital Bispebjerg and Frederiksberg
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmad Sajadieh
MD, DMSc
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmad Sajadieh, MD, DMSc
Role: PRINCIPAL_INVESTIGATOR
University Hospital Bispebjerg and Frederiksberg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bispebjerg Hospital
Copenhagen NV, Copenhagen, Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Larsen BS, Aplin M, Host N, Dominguez H, Christensen H, Christensen LM, Havsteen I, Prescott E, Jensen GB, Vejlstrup N, Bertelsen L, Sajadieh A. Atrial cardiomyopathy in patients with ischaemic stroke: a cross-sectional and prospective cohort study-the COAST study. BMJ Open. 2022 May 11;12(5):e061018. doi: 10.1136/bmjopen-2022-061018.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18055313
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.